---
title: "Embecta posts Q1 net income of USD 44.1 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274966514.md"
datetime: "2026-02-05T11:55:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274966514.md)
  - [en](https://longbridge.com/en/news/274966514.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274966514.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274966514.md) | [繁體中文](https://longbridge.com/zh-HK/news/274966514.md)


# Embecta posts Q1 net income of USD 44.1 million

Embecta Corporation (Nasdaq: EMBC) reported its financial results for the first quarter (Q1) of fiscal year 2026, covering the three months ended December 31, 2025. The company posted revenues of USD 261.2 million for the period. Gross profit for the quarter was USD 161.7 million. Operating income for Q1 FY2026 reached USD 83.3 million. Net income for the quarter was USD 44.1 million. Basic earnings per share stood at USD 0.75, while diluted earnings per share were USD 0.74. The company reported cash and equivalents of USD 201.3 million as of December 31, 2025. Embecta’s President and Chief Executive Officer, Devdatt Kurdikar, stated that the quarter’s results were largely consistent with expectations. He highlighted the company’s continued focus on transforming into a broad-based medical supplies company serving chronic care patients and drug delivery partners. Key initiatives include expanding the product portfolio, maintaining global leadership in core injection products, and enhancing financial flexibility through ongoing debt reduction. A dividend is scheduled to be paid on March 17, 2026, to stockholders of record as of February 27, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Embecta Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001872789-26-000005), on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [Embecta Corp. (EMBC.US)](https://longbridge.com/en/quote/EMBC.US.md)

## Related News & Research

- [Embecta to Acquire Owen Mumford for Up to £150 Million; £100 Million Upfront, Milestones Through 2028](https://longbridge.com/en/news/279922998.md)
- [NeurAxis Earnings Call: Reimbursement Wins Drive Next Phase](https://longbridge.com/en/news/279861750.md)
- [Nordea Investment Management AB Purchases 294,124 Shares of ResMed Inc. $RMD](https://longbridge.com/en/news/280049441.md)
- [EU Commission OKs Thermo Fisher Purchase of Clario](https://longbridge.com/en/news/279937391.md)
- [Telesia Extends Timetable for 2025 Accounts and Updates 2026 Financial Calendar](https://longbridge.com/en/news/279455103.md)